Verve Therapeutics (VERV) Short Interest Ratio & Short Volume → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free VERV Stock Alerts $5.24 -0.04 (-0.76%) (As of 05/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Verve Therapeutics Short Interest DataCurrent Short Interest17,590,000 sharesPrevious Short Interest16,540,000 sharesChange Vs. Previous Month+6.35%Dollar Volume Sold Short$109.59 millionShort Interest Ratio12.4 Days to CoverLast Record DateMay 15, 2024Outstanding Shares83,960,000 sharesFloat Size59,820,000 sharesShort Percent of Float29.40%Today's Trading Volume1,266,006 sharesAverage Trading Volume1,399,037 sharesToday's Volume Vs. Average90% Short Selling Verve Therapeutics ? Sign up to receive the latest short interest report for Verve Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVERV Short Interest Over TimeVERV Days to Cover Over TimeVERV Percentage of Float Shorted Over Time Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here Verve Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202417,590,000 shares $109.59 million +6.4%29.4%12.4 $6.23 4/30/202416,540,000 shares $99.41 million +5.4%30.2%12.6 $6.01 4/15/202415,690,000 shares $114.69 million +2.2%28.6%12.3 $7.31 3/31/202415,360,000 shares $203.98 million +8.9%28.0%12.3 $13.28 3/15/202414,100,000 shares $194.72 million +12.6%25.7%12.8 $13.81 2/29/202412,520,000 shares $213.47 million -0.6%22.9%11 $17.05 Get the Latest News and Ratings for VERV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/202412,590,000 shares $167.20 million +1.8%23.0%10.7 $13.28 1/31/202412,370,000 shares $133.84 million +0.1%21.9%7.7 $10.82 1/15/202412,360,000 shares $157.84 million +5.4%21.9%7.2 $12.77 12/31/202311,730,000 shares $163.52 million +4.4%22.9%7 $13.94 12/15/202311,240,000 shares $155.79 million -21.8%21.9%6.7 $13.86 11/30/202314,380,000 shares $162.21 million +7.7%28.0%9.2 $11.28 11/15/202313,350,000 shares $153.39 million +5.2%30.8%9.5 $11.49 10/31/202312,690,000 shares $152.79 million +11.1%29.6%13.2 $12.04 10/15/202311,420,000 shares $133.61 million -6.2%26.7%16 $11.70 9/30/202312,180,000 shares $161.51 million +2.0%28.4%18.2 $13.26 9/15/202311,940,000 shares $151.40 million +0.2%27.9%19.4 $12.68 8/31/202311,920,000 shares $153.41 million +6.7%28.2%18.6 $12.87 8/15/202311,170,000 shares $176.49 million +4.5%26.4%17.9 $15.80 7/31/202310,690,000 shares $219.04 million -10.2%26.5%17.2 $20.49 7/15/202311,900,000 shares $237.29 million +0.5%29.5%19.2 $19.94 6/30/202311,840,000 shares $222 million +2.5%29.3%18.3 $18.75 6/15/202311,550,000 shares $229.15 million -6.6%28.6%16.6 $19.84 5/31/202312,360,000 shares $191.33 million -1.9%30.6%17.8 $15.48 5/15/202312,600,000 shares $222.52 million -4.0%31.2%16.7 $17.66 4/30/202313,120,000 shares $209.00 million -2.3%34.5%17.5 $15.93 4/15/202313,430,000 shares $202.12 million -0.5%35.3%17.9 $15.05 3/31/202313,500,000 shares $194.67 million -1.5%35.6%18.3 $14.42 3/15/202313,700,000 shares $233.59 million No Change36.1%19.3 $17.05 2/28/202313,700,000 shares $260.30 million +1.0%36.1%17 $19.00 2/15/202313,570,000 shares $294.74 million +5.9%35.9%17.6 $21.72 1/31/202312,820,000 shares $291.66 million +0.2%31.6%13.9 $22.75 1/15/202312,790,000 shares $293.40 million +2.6%31.5%13.3 $22.94 12/30/202212,470,000 shares $241.29 million +13.8%32.5%13 $19.35 12/15/202210,960,000 shares $213.94 million +8.4%29.0%11.1 $19.52 11/30/202210,110,000 shares $234.86 million +1.3%26.7%9.4 $23.23 11/15/20229,980,000 shares $260.08 million -0.7%26.4%9.9 $26.06 10/31/202210,050,000 shares $378.89 million -6.3%26.9%9.6 $37.70 10/15/202210,730,000 shares $327.91 million -11.5%29.7%11.1 $30.56 9/30/202212,130,000 shares $416.67 million +23.0%33.6%10 $34.35Banking Apocalypse Ahead: Secure Your Savings Today! (Ad)During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. We warned about 484 — an accuracy rate of 99.8% Now, I have a new warning.See what it is here! 9/15/20229,860,000 shares $409.09 million +2.0%27.3%8.2 $41.49 8/31/20229,670,000 shares $370.94 million +0.8%27.7%8.8 $38.36 8/15/20229,590,000 shares $363.08 million +7.4%27.4%9 $37.86 7/31/20228,930,000 shares $219.86 million -10.0%30.4%8.8 $24.62 7/15/20229,920,000 shares $235.20 million +5.6%33.8%10.3 $23.71 6/30/20229,390,000 shares $143.48 million -5.5%37.7%13.6 $15.28 6/15/20229,940,000 shares $122.16 million +3.4%40.0%14.5 $12.29 5/31/20229,610,000 shares $145.69 million +2.2%38.8%13.7 $15.16 5/15/20229,400,000 shares $129.06 million +4.4%37.9%13.3 $13.73 4/30/20229,000,000 shares $134.28 million +6.6%36.0%13.4 $14.92 4/15/20228,440,000 shares $171.59 million -3.3%33.8%12 $20.33 3/31/20228,730,000 shares $199.22 million +7.6%35.2%12.3 $22.82 3/15/20228,110,000 shares $170.31 million +5.5%32.6%11.6 $21.00 2/28/20227,690,000 shares $251.08 million +0.9%31.0%12.2 $32.65 2/15/20227,620,000 shares $243.61 million +10.6%30.7%12.2 $31.97 1/31/20226,890,000 shares $198.57 million +11.3%27.6%11.8 $28.82 1/15/20226,190,000 shares $202.97 million +0.8%22.7%12.2 $32.79 12/31/20216,140,000 shares $226.38 million +8.5%22.5%14.3 $36.87 12/15/20215,660,000 shares $194.93 million +21.5%20.8%13.4 $34.44 11/30/20214,660,000 shares $158.81 million +21.4%17.1%12 $34.08 11/15/20213,840,000 shares $176.64 million +15.7%14.1%10.6 $46.00 10/29/20213,320,000 shares $154.01 million +11.4%12.4%9.6 $46.39 10/15/20212,980,000 shares $130.91 million +34.2%11.1%8.3 $43.93 9/30/20212,220,000 shares $104.34 million +17.5%8.3%5.4 $47.00 9/15/20211,890,000 shares $121.94 million +1.6%7.0%4.1 $64.52 8/31/20211,860,000 shares $130.13 million +17.0%7.6%3.9 $69.96 8/13/20211,590,000 shares $95.40 million No Change6.5%3.1 $60.00 VERV Short Interest - Frequently Asked Questions What is Verve Therapeutics' current short interest? Short interest is the volume of Verve Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 17,590,000 shares of VERV short. 29.40% of Verve Therapeutics' shares are currently sold short. Learn More on Verve Therapeutics' current short interest. What is a good short interest ratio for Verve Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VERV shares currently have a short interest ratio of 12.0. Learn More on Verve Therapeutics's short interest ratio. Which institutional investors are shorting Verve Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Verve Therapeutics: Ikarian Capital LLC, and PEAK6 Investments LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Verve Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 29.40% of Verve Therapeutics' floating shares are currently sold short. Is Verve Therapeutics' short interest increasing or decreasing? Verve Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 17,590,000 shares, an increase of 6.3% from the previous total of 16,540,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Verve Therapeutics' float size? Verve Therapeutics currently has issued a total of 83,960,000 shares. Some of Verve Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Verve Therapeutics currently has a public float of 59,820,000 shares. How does Verve Therapeutics' short interest compare to its competitors? 29.40% of Verve Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Verve Therapeutics: Adlai Nortye Ltd. (0.03%), Korro Bio, Inc. (2.81%), Esperion Therapeutics, Inc. (16.09%), Fulcrum Therapeutics, Inc. (4.97%), PepGen Inc. (1.61%), Oculis Holding AG (0.23%), Applied Therapeutics, Inc. (4.00%), Annexon, Inc. (8.19%), Theravance Biopharma, Inc. (13.37%), Neurogene Inc. (8.58%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Verve Therapeutics stock? Short selling VERV is an investing strategy that aims to generate trading profit from Verve Therapeutics as its price is falling. VERV shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Verve Therapeutics? A short squeeze for Verve Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VERV, which in turn drives the price of the stock up even further. How often is Verve Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VERV, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Adlai Nortye Short Interest Data Korro Bio Short Interest Data Esperion Therapeutics Short Interest Data Fulcrum Therapeutics Short Interest Data PepGen Short Interest Data Oculis Short Interest Data Applied Therapeutics Short Interest Data Annexon Short Interest Data Theravance Biopharma Short Interest Data Neurogene Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VERV) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeBill Clinton Backing Biden Replacement???The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.